Delivery Order 75A50119D00035-75A50324F63003

Award Date 9/19/24
Potential Completion Date 3/19/25
Potential Value $57M
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Morristown, NJ 07960, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Walsh Healy Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $1,417.10 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of oseltamivir phosphate 75 mg capsules, which are used to treat influenza. The delivery order is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a vehicle for...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4,566,307,107 units of the antiviral medication Oseltamivir Phosphate 75 mg capsules. The $5,284.09 firm-fixed-price contract has a completion date of November 4, 2024 and is not designated as a set-aside. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a...
This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of oseltamivir phosphate 75 mg capsules. The $1,116.37 firm fixed-price contract has an ultimate completion date of January 17, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with DLA Troop Support Medical, which serves as a primary vehicle for...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,567,247,518 units of the antiviral medication Oseltamivir Phosphate 75 mg capsules, a critical pharmaceutical product used in the prevention and treatment of influenza. The contract has a total ceiling value of $1,035.40 and a period of performance through February 13, 2025. It...
This federal contract award, issued by the Defense Logistics Agency (DLA), is a delivery order under the Indefinite Delivery Contract (IDC) held by AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,126.99 firm fixed-price contract is for the delivery of 4,566,703,864 units of Oseltamivir Phosphate 75 mg capsules, a medication used for the treatment of influenza. The contract has a performance period through December 13, 2024 and does not...
This is a federal contract award issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,262.36, is a delivery order for 4,567,154,351 units of the antiviral medication Oseltamivir Phosphate 75 mg capsules. The contract has a completion date of February 5, 2025 and is a firm fixed-price arrangement. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical company Amerisourcebergen Corporation, to provide 4,563,795,316 units of the drug Oseltamivir Phosphate 75 mg capsules. The $1,317.58 order is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 awarded to Amerisourcebergen Drug Corp by DLA to deliver a comprehensive range of pharmaceutical products and...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $33,241.62, is for the delivery of 4,564,331,528 units of Oseltamivir 75mg, a prescription medication used to treat influenza. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999, which serves as a primary vehicle for DLA...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, Corporate Office Division. The contract is for the supply of 4,565,901,325 units of the antiviral medication Oseltamivir Phosphate 75 mg capsules. The contract has a firm fixed price of $1,272.60 and a completion date of September 24, 2024. This delivery order is issued under a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide 4,563,283,081 units of the antiviral drug Oseltamivir Phosphate 75 mg capsules. The firm-fixed-price delivery order, valued at $1,382.20, has a completion date of January 10, 2024 and does not utilize any set-aside requirements. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a...
  • 75A50119D00035
    Indefinite Delivery Contract
  • 75A50119D00035-75A50324F63003
    Delivery Order

The U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a $57,099,989.22 Delivery Order to Alvogen, Inc., a for-profit manufacturer, to provide Oseltamivir Phosphate 75mg, 10 ct Blister (Adult Course). This Delivery Order is part of a larger $505 million single award Indefinite Delivery Contract with Alvogen to deliver the antiviral medication to the Strategic National Stockpile through August 2024. The contract has no set-aside designation and represents a critical partnership between the federal government and Alvogen to maintain readiness for an influenza pandemic by ensuring the stockpile of this essential medical countermeasure.

Generated 12/5/24, 10:35 AM